Acupoint Embedding of Polyglactin 910 Sutures in Patients with Chronic Pain due to Cervical Spondylotic Radiculopathy: A Multicenter, Randomized, Controlled Clinical Trial
Table 4
Secondary outcome measures (quality of life assessment).
Outcome Measure
SAE (n = 34)
MAPE (n = 34)
DAPE (n = 34)
Tukey’s Comparison
MAPE vs. SAE
DAPE vs. SAE
DAPE vs. MAPE
Diff. (95% CI)
P
Diff. (95% CI)
P
Diff. (95% CI)
P
The Physical Component Summary (PCS) of the SF36 health questionnaire, Mean ± SD
Baseline
56.4 ± 13.8
54.4 ± 13.8
57.4 ± 19.8
−2.0 (−10.1 to 6.1)
>.05
0.9 (−7.1 to 9.0)
>.05
3.9 (−5.1 to 12.9)
>.05
T 1w
56.9 ± 14.6
58.0 ± 14.4
59.8 ± 19.2
1.1 (−7.0 to 9.2)
>.05
2.9 (−5.2 to 10.9)
>.05
2.8 (−6.3 to 11.8)
>.05
T 2w
56.3 ± 14.5
68.9 ± 11.8
69.3 ± 13.8
12.6 (4.5 to 20.7)
<.001
13.0 (4.9 to 21.1)
<.001
1.6 (−7.5 to 10.6)
>.05
T 3w
56.7 ± 13.56
66.7 ± 11.4
75.7 ± 12.7
10.0 (1.9 to 18.1)
<.05
19.0 (11.0 to 27.1)
<.001
10.1 (1.0 to 19.1)
<.05
F 4w
57.0 ± 14.5
69.9 ± 11.8
69.0 ± 15.4
12.9 (4.8 to 21.0)
<.001
11.9 (3.9 to 20.0)
<.01
0.4 (−7.4 to 8.2)
>.05
F 10w
57.7 ± 13.9
75.2 ± 9.3
74.2 ± 13.1
17.5 (9.4 to 25.6)
<.001
16.5 (8.4 to 24.6)
<.001
−0.4 (−8.2 to 7.3)
>.05
P(t)
0.129
<.001
<.001
NA
The Mental Component Summary (MCS) of the SF36 health questionnaire, Mean ± SD
Baseline
55.7 ± 13.3
54.8 ± 14.6
56.9 ± 15.9
−0.9 (−8.2 to 6.4)
>.05
1.2 (−6.1 to 8.5)
>.05
2.1 (−5.2 to 9.4)
>.05
T 1w
57.9 ± 11.6
61.1 ± 17.4
63.4 ± 18.0
3.1 (−4.2 to 10.5)
>.05
5.4 (−1.9 to 12.8)
>.05
2.3 (−5.0 to 9.6)
>.05
T 2w
57.0 ± 11.6
76.6 ± 11.3
77.8 ± 11.5
19.6 (12.3 to 26.9)
<.001
20.8 (13.5 to 28.1)
<.001
1.1 (−6.2 to 8.5)
>.05
T 3w
57.3 ± 11.0
75.6 ± 8.9
76.9 ± 10.1
18.4 (11.1 to 25.7)
<.001
19.6 (12.3 to 26.9)
<.001
1.2 (−6.1 to 8.5)
>.05
F 4w
58.2 ± 12.2
63.3 ± 13.5
63.1 ± 10.9
5.0 (−2.3 to 12.4)
>.05
4.9 (−2.4 to 12.2)
>.05
−0.1 (−7.4 to 7.2)
>.05
F10w
58.7± 11.7
62.8 ± 11.1
64.5 ± 12.1
4.1 (−3.2 to 11.4)
>.05
5.8 (−1.5 to 13.1)
>.05
1.7 (−5.6 to 9.0)
>.05
P(t)
0.058
<.001
<.001
NA
SAE, sham acupoint embedding group; MAPE, middle-layer (the semispinalis capitis muscle layer) PGLA embedding group; DAPE, deep-layer (the multifidus muscle layer) PGLA embedding group; CI, confidence interval; NA, not applicable. 1w, 1 week; 2w, 2 weeks; 3w, 3 weeks; 4w, 4 weeks; 10w, 10 weeks; T, treatment; F, follow-up. P(t) refers to the p-values between different treatment time points.
